We experienced an infant with small bowel intussusception due to a rare pathological lead point. The two-month-old baby has admitted to our center with because of vomiting and bloody stool. Although an intraabdominal multicystic mass was suspected by abdominal ultrasonography, other examinations did not detect any abnormal findings. The infant was discharged but was readmitted one week later because of vomiting and transient impairment of consciousness. Although no ileocolic intussusception was visible by enema, abdominal computed tomography and ultrasonography clearly showed intestinal invagination. Emergency laparotomy was performed, whereupon a small bowel intussusception was observed. After surgical reduction, a small, palpable intramural mass was found at the lead point of the invagination, and the section of the intestine containing the mass was removed by wedge resection. The mass was multicystic and was diagnosed by immunohistochemistry as an intestinal submucosal cyst.
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.